Indications

Non-Hodgkin’s Lymphoma (NHL)

RIABNI™ (rituximab-arrx) is indicated for the treatment of adult patients with:
- Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent.
- Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy.
- Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy.
- Previously untreated diffuse large B-cell, CD20-positive NHL in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens.
Chronic Lymphocytic Leukemia (CLL)

RIABNI™, in combination with fludarabine and cyclophosphamide (FC), is indicated for the treatment of adult patients with previously untreated and previously treated CD20-positive CLL.
Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA)

RIABNI™, in combination with glucocorticoids, is indicated for the treatment of adult patients with Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA).

BEHIND RIABNI™ The amgen experience YOU'VE COME to trust

Introducing Riabni™

The rituximab biosimilar from Amgen, a proven leader in oncology biologics¹

Introducing Riabni™

The rituximab biosimilar from Amgen, a proven leader in oncology biologics¹

RIABNI™ is FDA approved for all Rituxan® oncology indications^1,2,*

Non-Hodgkin's lymphoma (NHL)
- - Follicular lymphoma (FL)
- - Previously untreated large B-cell lymphoma
- - Non-progressing (stable disease)
Previously untreated chronic lymphocytic leukemia (CLL)

FDA = Food and Drug Administration.
*RIABNI™ is also indicated for the treatment of Granulomatosis with Polyangiitis (GPA) (Wegener's granulomatosis) and Microscopic Polyangiitis (MPA) in adult patients.

BEHIND RIABNI™ The amgen experience YOU'VE COME to trust

BEHIND RIABNI™ The amgen experience YOU'VE COME to trust

Introducing Riabni™

The rituximab biosimilar from Amgen, a proven leader in oncology biologics1

Introducing Riabni™

The rituximab biosimilar from Amgen, a proven leader in oncology biologics1

RIABNI™ (rituximab-arrx) has anestablished Q-Code:

Important Safety Information

BOXED WARNINGS: FATAL INFUSION-RELATED REACTIONS, SEVERE MUCOCUTANEOUS REACTIONS, HEPATITIS B VIRUS REACTIVATION, PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY

Infusion-Related Reactions (IRR)

Severe Mucocutaneous Reactions

Hepatitis B Virus Reactivation

Progressive Multifocal Leukoencephalopathy (PML)

Tumor Lysis Syndrome

Infections

Cardiovascular Adverse Reactions

Renal Toxicity

Bowel Obstruction and Perforation

Immunization

Embryo-Fetal Toxicity

Concomitant Use with Other Biologic Agents and Disease Modifying Antirheumatic Drugs (DMARDs) in GPA and MPA

Adverse Reactions

Nursing Mothers

Clinical Trials Experience in GPA and MPA

Induction Treatment of Patients with Active GPA/MPA (GPA/MPA Study 1) Infusion-Related Reactions

Infections

Hypogammaglobulinemia

Immunogenicity

Treatment of Patients with GPA/MPA Who Have Achieved Disease Control with Induction Treatment (GPA/MPA Study 2)

Infusion-Related Reactions (IRR)

Infections

Attention Healthcare Provider: Provide Medication Guide to patient prior to RIABNI™ infusion and advise patients to read guide.

Indications

Non-Hodgkin’s Lymphoma (NHL)

Chronic Lymphocytic Leukemia (CLL)

Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA)

Important Safety Information

BOXED WARNINGS: FATAL INFUSION-RELATED REACTIONS, SEVERE MUCOCUTANEOUS REACTIONS, HEPATITIS B VIRUS REACTIVATION, PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY

Infusion-Related Reactions (IRR)

Severe Mucocutaneous Reactions

Hepatitis B Virus Reactivation

Progressive Multifocal Leukoencephalopathy (PML)

Tumor Lysis Syndrome

Infections

Cardiovascular Adverse Reactions

Renal Toxicity

Bowel Obstruction and Perforation

Immunization

Embryo-Fetal Toxicity

Concomitant Use with Other Biologic Agents and Disease Modifying Antirheumatic Drugs (DMARDs) in GPA and MPA

Adverse Reactions

Nursing Mothers

Clinical Trials Experience in GPA and MPA

Induction Treatment of Patients with Active GPA/MPA (GPA/MPA Study 1) Infusion-Related Reactions

Infections

Hypogammaglobulinemia

Immunogenicity

Treatment of Patients with GPA/MPA Who Have Achieved Disease Control with Induction Treatment (GPA/MPA Study 2)

Infusion-Related Reactions (IRR)

Infections

Attention Healthcare Provider: Provide Medication Guide to patient prior to RIABNI™ infusion and advise patients to read guide.

Indications

Non-Hodgkin’s Lymphoma (NHL)

Chronic Lymphocytic Leukemia (CLL)

Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA)

Connect with an Amgen Oncology representative

Privacy Statement

The rituximab biosimilar from Amgen, a proven leader in oncology biologics¹

The rituximab biosimilar from Amgen, a proven leader in oncology biologics¹

RIABNI™
(rituximab-arrx) has an
established Q-Code: